1 / 43

HEADACHE

HEADACHE. Andrew Charles, M.D. Professor Director, Headache Research and Treatment Program David Geffen School of Medicine at UCLA. COMMON TYPES OF HEADACHES. PRIMARY HEADACHES MIGRAINE TENSION TYPE CLUSTER HEADACHE AND OTHER TRIGEMINAL AUTONOMIC CEPHALGIAS SECONDARY HEADACHES

jana
Download Presentation

HEADACHE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HEADACHE Andrew Charles, M.D. Professor Director, Headache Research and Treatment Program David Geffen School of Medicine at UCLA

  2. COMMON TYPES OF HEADACHES • PRIMARY HEADACHES • MIGRAINE • TENSION TYPE • CLUSTER HEADACHE AND OTHER TRIGEMINAL AUTONOMIC CEPHALGIAS • SECONDARY HEADACHES • Headaches due to infection • Headaches due to vascular causes • Headaches due to tumors • Etc., etc.

  3. HEADACHE: Prevalence and Impact PREVALENCE • 18-25 % women have migraine • 6-10 % men have migraine • 5% of women have headache more than 15 days per month • 112 million bedridden days per year • Cost to U.S. Employers -- $13 Billion per year • The majority of patients with migraine have not received an appropriate diagnosis, and are not receiving appropriate therapy

  4. MIGRAINE – A MULTISYMPTOM COMPLEX PAIN Sensory, Cognitive, Motor Symptoms VISUAL SYMPTOMS PATHOPHYSIOLOGICAL EVENTS Nausea/Vomiting VESTIBULAR SYMPTOMS PAIN

  5. CHANGING CONCEPTS OF MIGRAINE PATHOGENESIS • MIGRAINE IS A DISORDER OF BRAIN EXCITABILITY • VASODILATION MAY OCCUR AS PART OF THE DISORDER, BUT IS NOT REQUIRED FOR MIGRAINE PAIN

  6. Penfield W. A contribution to the mechanism of intracranial pain. Assoc Res NervMent Dis. 1935;15:399-416. • Ray BS, Wolff HG. Experimental studies in headache: Pain-sensitive structures of the head and their significance in headache. Arch Surg. 1940;41:813-856.

  7. Issues with Studies of Ray and Wolff, Penfield • Stimulation of vessels was focal external stimulation or mechanical dilation • There is no evidence that physiological relaxation of smooth muscle and resultant dilation can cause pain • Multiple areas of brain that could evoke pain were not stimulated: • Cingulate cortex • Brainstem – Stimulation or lesions in brainstem can cause migraine

  8. Vasoactive Drugs Cause Migraine After Significant Delay (hours), Not Correlated with Vasodilation • Nitric oxide donors • PDE inhibitors • Histamine • CGRP Schoonman, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study. Brain 131, 2192-2200, 2008. Kruus, et al. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 26:241-247, 2003. Rahman et al., Vasoactive intestinal peptide causes marked cerebral vasodilation but does not induce migraine. Cephalalgia. 28, 226-236, 2008.

  9. Alternative Mechanisms of“ Vascular” Drugs • -blockers • Inhibit neuronal adrenergic signaling • Calcium channel blockers • Inhibit neuronal calcium channels • Caffeine • Neuronal/glial adenosine receptor antagonist • Ergotamines • Modulate central 5-HT receptors • Triptans • Activate neuronal 5-HT1 receptors in brainstem and thalamus

  10. CORTICAL “WAVES” IN MIGRAINE WITH AURA Olesen, et al. 1981 Hadjikhani et al., 2001 Bereczki et al., 2008 Cao et al., 1999

  11. …AND MIGRAINE WITHOUT AURA Woods et al., 1994 After sumatriptan 4 to 6 h after the attack onset Before sumatriptan 2 to 4 h after the attack onset Chalaupka, 2008 Denuelle et al., 2008

  12. MIGRAINE – A MULTISYMPTOM COMPLEX PAIN Sensory, Cognitive, Motor Symptoms VISUAL SYMPTOMS Cortical Activation Brainstem Activation Nausea/Vomiting VESTIBULAR SYMPTOMS PAIN

  13. MIGRAINE SHOULD BE IN DIFFERENTIAL DIAGNOSIS OF ANY EPISODIC NEUROLOGICAL DISORDER

  14. Do most headache patients need an imaging study of the brain?

  15. “I’ll want to get a few tests on you, just to cover my ass”

  16. When Don’t You Need to Get a Scan? • Patient with established history of episodic headache • Current headache is consistent with previous headaches or is consistent with different manifestation of a primary headache. • Normal neurological exam

  17. When You Do Need to Get a Scan • Extremely abrupt onset of headache • Persistent unremitting headache • New onset of headache in patient over age of 50 • Fever • Papilledema • Abnormal neurological examination

  18. General Approach to The Headache Patient • Make a diagnosis (or challenge the diagnosis that a patient has already been given) • Identify and change exacerbating environmental factors and medications • Establish regimen for acute therapy of headache • Determine if preventive therapy is appropriate

  19. IHS CRITERIA FOR MIGRAINE WITHOUT AURA • At least 5 attacks fulfulling the following: • Headaches lasting 4 to 72 hours • During headache, at least one of the following: Nausea and/or vomiting Photophobia and phonophobia • At least 2 of the following criteria Unilateral location Pulsating quality Moderate or severe intensity Aggravated by physical activity

  20. Simplified Diagnostic Criteria:ID Migraine • Light sensitivity with headache • Nausea with headache • Decreased ability to function with headache • Any 2 out of 3 = Migraine Migraine should be the default diagnosis for any headache that is brought to the attention of a health care provider

  21. Migraine: Other Features • Perimenstrual timing • Stereotypical prodromal symptoms • Characteristic triggers • Abatement with sleep • Childhood precursors (motion sickness, somnambulism, episodic vomiting, episodic vertigo) • Osmophobia • Diarrhea during attack

  22. Landmark: How Likely Is it That “Headache” Is Migraine? • In a prospective, open-label study of 1203 patients with episodic headache • 94% (of 377 evaluable patients) had migraine or probable migraine • 25% with migraine were not diagnosed by their physician • Headaches had a severe impact (HIT–6 score 64) Probable migraine (n=67) 18% Migraine (n=288) 76% Episodic tension-type (n=11) 3% Unclassifiable (n=11) 3% Adapted from Tepper SJ et al. Headache. 2004;44:856–864.

  23. Patient If patient self-reports migraine, 99.5% chance migraine or probable migraine If patient self-reports non-migraine, 86% chance migraine or probable migraine Physician If physician diagnoses migraine, 98% chance migraine or probable migraine If physician diagnoses non-migraine, 82%chance migraine or probable migraine Landmark: Patient and Physician Diagnoses In a prospective, open-label study of 1203 patients with episodic headache • Self-report or physician diagnosis of migraine was almost always correct • Self-report or physician diagnosis of non-migraine was almost always later found out to be migraine Adapted from Tepper SJ et al. Headache. 2004;44:856–864.

  24. MIGRAINES ARE OFTEN MISDIAGNOSED • SINUS HEADACHES • SIMILAR DISTRIBUTION OF PAIN • MIGRAINES CAN BE SEASONAL • DECONGESTANTS CAN “TAKE THE EDGE OFF” OF MIGRAINE • WITHDRAWAL FROM DECONGESTANTS CAN PRECIPITATE MIGRAINES

  25. “SINUS HEADACHE”

  26. OTHER COMMON MIGRAINE MISDIAGNOSES • TENSION HEADACHE/CERVICOGENIC HEADACHE • NECK PAIN IS A SYMPTOM OF MIGRAINE • MIGRAINE COMMONLY ASSOCIATED WITH NECK PAIN • NECK PAIN MAY OCCUR BEFORE, DURING, OR AFTER HEADACHE

  27. ARE THERE MIGRAINE TRIGGERS?

  28. COMMON HEADACHE TRIGGERS • IRREGULAR MEALS • IRREGULAR CAFFEINE, CHOCOLATE, NUTS, BANANAS, ETC. • IRREGULAR SLEEP (PARTICULARLY EXCESSIVE SLEEP) • STRESS OR “LET-DOWN” FROM STRESS • AIR TRAVEL, CHANGE IN BAROMETRIC PRESSURE • MENSTRUAL PERIOD

  29. THE MIGRAINE LIFESTYLE • CONSISTENCY • TIMING OF MEALS, BALANCE OF DIET –- Don’t skip meals, mix of different food groups • SLEEP --- Don’t oversleep or undersleep • CAFFEINE – “Minimum daily dose” of caffeine on a daily basis • EXERCISE – The more aerobic exercise the better

  30. MEDICATIONS THAT MAY MAKE MIGRAINES WORSE • ORAL CONTRACEPTIVES • HORMONE REPLACEMENT • SSRI ANTIDEPRESSANTS • STEROIDS (TAPERING) • DECONGESTANTS • SHORT ACTING SEDATIVES (e.g. Ambien (?) • BONE DENSITY MEDICATIONS (?) • BOTOX

  31. FREQUENT OPIOID OR BARBITURATE (BUTALBITAL) USE IS A RISK FACTOR FOR MIGRAINE PROGRESSION • GROWING EVIDENCE THAT OVERUSE OF ANALGESIC MEDICATIONS LEADS TO WORSENING OF MIGRAINE • AMPP DATA (Bigal et al., Neurology 2008) • Frequent use of opioids or butalbital (more than 8 days/month) is a risk factor for progression to chronic migraine • Triptan use is neutral for progression • Nonsteroidal use is protective

  32. ACUTE THERAPIES • TRIPTANS – Selective 5HT 1b 1d agonists • SUMATRIPTAN (IMITREX TABLETS, NASAL SPRAY, INJECTION), SUMATRIPTAN NAPROXEN COMBINATION • RIZATRIPTAN (MAXALT “MELTABS”, TABLETS) • NARATRIPTAN (AMERGE TABLETS) • ZOLMITRIPTAN (ZOMIG) • ALMOTRIPTAN (AXERT) • FROVATRIPTAN (FROVA) • ELETRIPTAN (RELPAX) • DHE NASAL SPRAY (MIGRANAL), INJECTION • NSAIDS • METACLOPRAMIDE

  33. TRIPTAN NEWS • TRIPTANS ARE NOW AVAILABLE WIDELY WITHOUT A PRESCRIPTION IN EUROPE. • SUMATRIPTAN WILL SOON BE AVAILABLE AS A GENERIC IN MULTIPLE PREPARATIONS. • SUMATRIPTAN/NAPROXEN COMBINATION TABLET (TREXIMET) IS NOW AVAILABLE.

  34. EVIDENCE-BASED NON-PRESCRIPTION APPROACHES TO MIGRAINE • Magnesium (300-500 mg. per day) • Riboflavin (400 mg. per day) • CoQ10 (300 -1200 mg. per day) • Melatonin (3 mg. qhs) • Petasites (Butterbur 75 mg. BID)

  35. THERAPEUTIC OPTIONS FOR MIGRAINE PROPHYLAXIS • BETA BLOCKERS • TRICYCLICS • CALCIUM CHANNEL BLOCKERS • VALPROIC ACID (Depakote) • TOPIRAMATE (Topamax) • ?? MEMANTINE

  36. MEMANTINE FOR MIGRAINE PREVENTION? • Activity dependent blocker of NMDA receptors • Identified as a blocker of CSD in rodents • Appears to be effective as a migraine preventive therapy for significant percentage of patients with frequent migraine who had failed other preventive therapies • It is generally very well tolerated • Well designed studies are warranted Peeters et al., JPET, 2007 Charles, et al., Journal of Headache and Pain, 2007 Bigal et al., Headache, 2008

  37. MIGRAINE AND PREGNANCY • THE SIGNIFICANT MAJORITY OF WOMEN HAVE AN IMPROVEMENT IN MIGRAINE FREQUENCY DURING THE 2nd and 3rd TRIMESTERS OF PREGNANCY • THERE IS NO CONSENSUS OR EVIDENCED BASED APPROACH TO TREATMENT OF HEADACHE DURING PREGNANCY • REGULAR SMALL AMOUNTS OF CAFFEINE, MAGNESIUM SUPPLEMENTATION ARE REASONABLE NON-PRESCRIPTION ALTERNATIVES • THE ONLY ADVERSE EVENT THAT HAS BEEN IDENTIFIED WITH TRIPTANS AND PREGNANCY IS A SLIGHTLY INCREASED RISK OF PREMATURE DELIVERY….i.e. OK TO USE TRIPTANS IN SEVERE CASES

  38. NEW THERAPIES ON THE HORIZON • ACUTE THERAPIES • CGRP Antagonist – Initial placebo controlled trials look very promising. • Transcranial magnetic stimulation • Inhaled ergotamines • PREVENTIVE THERAPIES • PFO Closure – Multiple closure devices in clinical trials • Memantine – Initial uncontrolled results are promising • Occiptial nerve stimulation • Tonabersat

  39. CGRP (Calcitonin Gene Related Peptide)IN MIGRAINE • CGRP IS RELEASED INTO JUGULAR VENOUS SYSTEM DURING A MIGRAINE ATTACK • CGRP RECEPTOR ANTAGONISTS EFFECTIVELY ABORT A MIGRAINE ATTACK • Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. NEJM, 350: 1104-1110, 2004. JesOlesen, M.D., Hans-ChristophDiener, M.D., Ingo W. Husstedt, M.D., Peter J. Goadsby, M.D., David Hall, Ph.D., Ulrich Meier, Ph.D., StephanePollentier, M.D., and Lynna M. Lesko, M.D., for the BIBN 4096 BS Clinical Proof of Concept Study Group • Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70: 1304-1312, 2008. T. W. Ho, MD, L. K. Mannix, MD, X. Fan, PhD, C. Assaid, PhD, C. Furtek, BS, C. J. Jones, MS, C. R. Lines, PhD, A. M. Rapoport, MD On behalf of the MK-0974 Protocol 004 study group*

  40. POTENTIAL NEW THERAPIES FOR MIGRAINE INHIBITORS OF CORTICAL SPREADING DEPRESSION Memantine, Tonabersat, Transcranial Magnestic Stimulation INHIBITORS OF CGRP RECEPTOR Telcagepant CIRCULATORY TRIGGERS TO BRAIN EXCITABILITY? PFO Closure MODULATORS OF CERVICAL INPUT TO HEADACHE Occipital Nerve Stimulation Adapted from Jones HR. Netter’s Neurology, St. Louis, MO; Saunders; 2005.

  41. TAKE HOME MESSAGES • MIGRAINE IS A COMPLEX DISORDER OF BRAIN EXCITABILITY AND NOT SIMPLY A “VASCULAR HEADACHE” • MIGRAINE IS EXTRAORDINARILY COMMON AND UNDERDIAGNOSED. • THE MAJORITY OF MIGRAINE PATIENTS CAN BE EFFECTIVELY AND SAFELY TREATED WITH AN ORGANIZED PLAN OF LIFESTYLE MANAGEMENT , ACUTE THERAPY, AND PREVENTIVE THERAPY IF NEEDED • PROMISING NEW THERAPIES ARE ON THE HORIZON

More Related